SCOPUS 정보 검색 플랫폼

Volumn 89, Issue 4, 2010, Pages 425-426

Treatment of 5q-syndrome with lenalidomide in an HIV-positive patient under cART

(6) Blum, Sabine a Cavassini, Matthias a Lambert, Jean François a Fayet, Aurélie a Schapira, Marc a Jotterand, Martine a

a LAUSANNE UNIVERSITY HOSPITAL (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; LENALIDOMIDE; LOPINAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; THALIDOMIDE;

5Q- SYNDROME; ADULT; CASE REPORT; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRON OVERLOAD; LETTER; LYMPHOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; PHLEBOTOMY; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; CHROMOSOME 5; CHROMOSOME DELETION; DRUG COMBINATION; IMMUNOLOGY; LYMPHOCYTE; MIDDLE AGED; PATHOLOGY; VIROLOGY;

ANTI-HIV AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; THALIDOMIDE;

EID: 77649306301 PISSN: 09395555 EISSN: None Source Type: Journal
DOI: 10.1007/s00277-009-0815-6 Document Type: Letter

Times cited : (2)

References (6)

1
- 33749438404
- Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
- List A, Dewald G, Bennett J et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465
- (2006) N Engl J Med , vol.355 , pp. 1456-1465
- List, A.¹ Dewald, G.² Bennett, J.³

2
- 0033168605
- Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
- Corral LG, Haslett PA, Muller GW et al (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163:380-386
- (1999) J Immunol , vol.163 , pp. 380-386
- Corral, L.G.¹ Haslett, P.A.² Muller, G.W.³

3
- 0037444106
- Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro
- Haslett PA, Hanekom WA, Muller G et al (2003) Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 187:946-955
- (2003) J Infect Dis , vol.187 , pp. 946-955
- Haslett, P.A.¹ Hanekom, W.A.² Muller, G.³

4
- 41549102420
- Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
- Giagounidis A, Fenaux P, Mufti GJ et al (2008) Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 87:345-352
- (2008) Ann Hematol , vol.87 , pp. 345-352
- Giagounidis, A.¹ Fenaux, P.² Mufti, G.J.³

5
- 8244247121
- Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
- National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group
- Jacobson JM, Greenspan JS, Spritzler J et al (1997) Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 336:1487-1493
- (1997) N Engl J Med , vol.336 , pp. 1487-1493
- Jacobson, J.M.¹ Greenspan, J.S.² Spritzler, J.³

6
- 0037159878
- Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing
- Teo S, Noormohamed F, Youle M et al (2002) Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing. Aids 16:2355-2356
- (2002) Aids , vol.16 , pp. 2355-2356
- Teo, S.¹ Noormohamed, F.² Youle, M.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.